All Press Releases for August 09, 2014

Australia Grants Medical Device Patent for babyLance Safety Heelstick

Reinforces MediPurpose's Commitment to Supporting Australian Sharps Safety

We are very keen to participate in Australia's interest in the adoption of sharps safety devices that prevent accidental needlestick injuries.

    CANBERRA, AUSTRALIA, August 09, 2014 /24-7PressRelease/ -- MediPurpose(tm), a master distributor and manufacturer of medical products, today announced that it has received an Australian medical device patent for its babyLance(tm) safety heelstick.

IP Australia recently granted patent 2009277209 to MediPurpose for its novel neonatal incision device, which expands the company's intellectual property (IP) protection in Australia. MediPurpose also has Australian trademark protection for babyLance, as well as for MediPlus(tm) Advanced Wound Care products.

"Our pursuit of medical device patents in Australia and elsewhere is not just intended to protect our medical device IP," said MediPurpose founder and CEO Patrick Yi. "It's also an expression of our commitment to either serving the countries in which we distribute our medical products, or our intention to secure relationships with medical product distributors in them."

Those commitments and intentions have been at the forefront of the company's recent headlines, particularly as its new relationship with IVD Export Consultants (IVDEC) continues to evolve. In June, MediPurpose announced that IVDEC would begin providing marketing and sales support for its products in Europe, the Middle East, Africa, Asia and Australia (EMEA). Last month, it expanded IVDEC's territories to include Latin America.

Anticipating Adoption of Australian Sharps Safety Regulations
An estimated 18,000 Australian nurses and healthcare workers endure accidental needlestick and sharps injuries each year, according to the Alliance for Sharps Safety and Needlestick Prevention in Healthcare. Although Australia doesn't have laws and regulations that mandate the use of safety engineered medical devices -- such as the U.S. Needlestick Safety and Prevention Act or Brazil's NR 32 -- the Alliance is urging a national call to action for similar legislation.

"We are very keen to participate in Australia's interest in the adoption of sharps safety devices that prevent accidental needlestick injuries," said Yi. "Securing intellectual property for babyLance in Australia -- and partnering with IVDEC -- advances that mission."

About babyLance(tm) Safety Heelsticks
babyLance safety heelsticks are single-use safety neonatal needlestick devices for the collection of blood from infants.

Specifically designed to meet neonatal nurses' expectations for the ideal heelstick, babyLance provides enhanced stability, comfort and ease of use.

babyLance is available in two models, each with a specific blade penetration:

- babyLance BLP (preemie): 0.85 mm depth
- babyLance BLN (newborn): 1.0 mm depth

For more information about babyLance safety heelsticks -- including no-cost product sample requests -- please visit

About MediPurpose
Founded in 1999, MediPurpose is an innovative medical device company headquartered in Singapore, with offices in the United States and Europe.

Known for its popular babyLance(tm) safety heelstick, SurgiLance(tm) safety lancet and MediPlus(tm) advanced wound care products, MediPurpose has leveraged its success in the medical device industry to become a master medical product distributor that provides unique solutions for both medical product manufacturers and distributors.

MediPurpose's Medical Device Innovation division offers angel funding and developmental expertise for new medical device inventors and innovative medical product companies that seek entrance into new medical device markets.

For more information about MediPurpose's medical products and solutions for inventors, innovators, manufacturers and distributors, please visit

# # #

Contact Information

Derek Rudnak
MediPurpose Inc.
Duluth, GA
Voice: 888-808-6494
E-Mail: Email Us Here
Website: Visit Our Website
Blog: Visit Our Blog
Follow Us:

Comment on this story...